Semaglutide: The truth behind Wegovy, Alzheimer’s and what no influencer tells you

If you've been keeping up with health trends or simply walked past a pharmacy in recent months, you've definitely heard about semaglutide. It's that complicated name everyone associates with the famous weight-loss pen, but trust me, the story goes far beyond mirror selfies or the miracle prescriptions we see on social media. As someone who's covered the pharmaceutical sector for years, I'm going to tell you what's really happening, especially after data was leaked at international conferences that gave the conversation an unexpected turn.

The boom of the famous "pen" and what it hides

The arrival of drugs like Wegovy and Ozempic revolutionised the way we view the treatment of diabetes and obesity. In the streets of Australia's cities, it's not uncommon to hear someone asking for Wegovy 0.25mg, that specific presentation that comes in a box with an application system filled with 1.5mL of solution for subcutaneous use plus 4 Novofine Plus needles. It's the starting dose, the one many people seek to begin treatment. But here's the first hard truth: this is not a toy. When you see semaglutide being sold as the magic solution to lose five kilos in a month without breaking a sweat, it makes my skin crawl. Because it's a potent drug, and like any potent drug, it has its rules.

The news no one expected: Goodbye to the hope for Alzheimer's?

A few months ago, the scientific community was buzzing with excitement. There was genuine hope that semaglutide would not only help with weight or glucose but could also act as a shield against Alzheimer's. There was talk of studies suggesting a neuroprotective effect, that it could slow cognitive decline. It seemed like finding an added bonus to something that was already working. However, as in life itself, reality has just given us a harsh dose of it.

Just a few weeks ago, during the finalisation of the phase III clinical trials we were all eagerly awaiting, the conclusion was clear: semaglutide failed to slow the progression of mild Alzheimer's. It hurt to read the internal report, because I know that many families in Australia, caring for loved ones with this disease, had pinned their hopes on this. The data, which we handle carefully in the industry, showed that while the drug works wonders on metabolism, when it comes to memory loss and cognitive functions, there was simply no significant difference between those taking the drug and those receiving a placebo. It's a dead stop for one of the most exciting hypotheses put forward in recent years.

What you should know if you're already using semaglutide

The fact that it doesn't work for Alzheimer's doesn't take away from its effectiveness for what it was approved for. But this is where I want to get serious with you, because in my experience, people tend to skip steps. If you're considering using Wegovy 0.25mg or any presentation, keep this in mind:

• It's not for everyone: The initial 0.25mg dose is designed to let your body adjust. Skipping doses or starting with a higher one can land you straight in hospital with pancreatitis.
• The application system isn't optional: That "pre-filled application system with 1.5mL of subcutaneous solution" isn't just a fancy extra. The way it's administered and the Novofine Plus needles are designed to minimise pain and ensure the dose is correct.
• It's a treatment, not a one-month fad: Semaglutide works while you're using it. I've seen cases of people using it for an event and then stopping, only to regain the weight and then some. This is a long-term commitment, if your doctor determines it's right for you.

The Australian factor and the grey market

Here in Australia, we have a particular relationship with medication. We tend towards self-prescription and the famous "just give me a little bit, even if it's a small amount." With semaglutide, this has been chaotic. I've seen sellers on social media offering "generic Wegovy" or the "version for diabetics" as if they were lollies. I'm telling you this with the confidence of someone who has seen both sides of the coin: don't take the risk. The Novofine Plus needles that come in the official box aren't a luxury; they're part of a safety protocol. Buying this on the informal market is playing Russian roulette with your health.

The failure of the studies to halt Alzheimer's isn't bad news per se, but rather an invitation to come back down to earth. Science advances, sometimes with setbacks, but it continues to advance. Semaglutide is an incredibly useful tool for those who truly need it under medical supervision. For everyone else, the lesson is clear: don't look for shortcuts, especially when it comes to your brain and your wellbeing. If your doctor prescribed it, trust the process, respect the doses, and that subcutaneous application system. If you only want it as a trend, perhaps now is the time to sit and think about whether it's worth playing with fire.